Test

This is a test

Search by drug, manufacturer, or indication

Displaying 881 - 890 of 1165

Lancora (ivabradine)

Status:

Concluded with an LOI

Manufacturer:

Servier Canada Inc.

Indication:

Heart failure, NYHA class II or III

Last updated August 22, 2018

Actikerall (fluorouracil/salicylic acid)

Status:

Concluded with an LOI

Manufacturer:

Cipher

Indication:

Hyperkeratotic actinic keratosis

Last updated August 22, 2018

Rituxan SC (rituximab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Chronic lymphocytic leukemia

Last updated August 13, 2018

Revestive (teduglutide)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Short Bowel Syndrome (SBS)

Last updated August 7, 2018

Praluent (alirocumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Primary hypercholesterolemia (non-familial and heterozygous familial)

Last updated August 2, 2018

Tagrisso (osimertinib)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated July 30, 2018

Renflexis (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Rheumatic Conditions

Last updated July 27, 2018

Tresiba (insulin degludec)

Status:

Concluded with an LOI

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated July 26, 2018

Pomalyst (pomalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma

Last updated July 25, 2018

Procysbi (cysteamine bitartrate)

Status:

Concluded with an LOI

Manufacturer:

Horizon Therapeutics Ireland DAC

Indication:

Nephropathic cystinosis

Last updated July 20, 2018